



# Mirataz™ (mirtazapine transdermal ointment)

For topical application in cats only. Not for oral or ophthalmic use.

**CAUTION:** Federal law (USA) restricts this drug to use by or on the order of a licensed veterinarian.

**Before using this product, please consult the product insert, a summary of which follows:**

**INDICATION:** Mirataz™ is indicated for the management of weight loss in cats.

**DOSAGE AND ADMINISTRATION:** Administer topically by applying a 1.5-inch ribbon of ointment (approximately 2 mg/cat) on the inner pinna of the cat's ear once daily for 14 days. Wear disposable gloves when applying Mirataz™. Alternate the daily application of Mirataz™ between the left and right inner pinna of the ears. **See Product Insert for complete dosing and administration information.**

**CONTRAINDICATIONS:** Mirataz™ is contraindicated in cats with a known hypersensitivity to mirtazapine or to any of the excipients. Mirataz™ should not be given in combination, or within 14 days before or after treatment with a monoamine oxidase inhibitor (MAOI) [e.g. selegiline hydrochloride (L-deprenyl), amitraz], as there may be an increased risk of serotonin syndrome.

**HUMAN WARNINGS:** Not for human use. Keep out of reach of children. **Wear disposable gloves when handling or applying Mirataz™ to prevent accidental topical exposure.** After application, dispose of used gloves and wash hands with soap and water. After application, care should be taken that people or other animals in the household do not come in contact with the treated cat for 2 hours because mirtazapine can be absorbed transdermally and orally. However, negligible residues are present at the application site and the body of the cat at 2 hours after dosing. In case of accidental skin exposure, wash thoroughly with soap and warm water. In case of accidental eye exposure, flush eyes with water. If skin or eye irritation occurs seek medical attention. In case of accidental ingestion, or if skin or eye irritation occurs, seek medical attention.

**PRECAUTIONS:** Do not administer orally or to the eye. Use with caution in cats with hepatic disease. Mirtazapine may cause elevated serum liver enzymes (See **Animal Safety** in the product insert). Use with caution in cats with kidney disease. Kidney disease may cause reduced clearance of mirtazapine which may result in higher drug exposure. Upon discontinuation of Mirataz™, it is important to monitor the cat's food intake. Food intake may lessen after discontinuation of mirtazapine transdermal ointment. If food intake diminishes dramatically (>75%) for several days, or if the cat stops eating for more than 48 hours, reevaluate the cat. Mirataz™ has not been evaluated in cats < 2 kg or less than 6 months of age. The safe use of Mirataz™ has not been evaluated in cats that are intended for breeding, pregnant or lactating cats.

**ADVERSE REACTIONS:** In a randomized, double-masked, vehicle-controlled field study to assess the effectiveness and safety of mirtazapine for the management of weight loss in cats, 115 cats treated with Mirataz™ and 115 cats treated with vehicle control were evaluated for safety. The vehicle control was an ointment containing the same inert ingredients as Mirataz™ without mirtazapine. The most common adverse reactions included application site reactions, behavioral abnormalities (vocalization and hyperactivity), and vomiting. **See Product Insert for complete Adverse Reaction information.** To report suspected adverse events, for technical assistance or to obtain a copy of the SDS, contact Kindred Biosciences, Inc. at 888-608-2542. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at <http://www.fda.gov/AnimalVeterinary/SafetyHealth>.

**EFFECTIVENESS:** The effectiveness of Mirataz™ (mirtazapine transdermal ointment) was demonstrated in a randomized, double-masked, vehicle-controlled, multi-site field study involving client-owned cats of various breeds. Enrolled cats were ≥ 1 year of age and had existing documented medical history of ≥ 5% weight loss deemed clinically significant. The most common pre-existing conditions included renal insufficiency, vomiting, and hyperthyroidism. Some cats had more than one pre-existing condition. Cats were randomized to treatment groups in a 1:1 ratio of Mirataz™ to vehicle control. A total of 230 cats were enrolled and received either Mirataz™ (115 cats) or a vehicle control (115 cats) containing the same inert ingredients without mirtazapine. The cats were 2.8-24.6 years of age and weighed 2.1-9.2 kg. The dosage was a 1.5-inch ribbon (approximately 2 mg/cat) mirtazapine or vehicle ointment administered topically to the inner pinna of the cat's ear. A total of 177 cats were determined to be eligible for the effectiveness analysis; 83 cats were in the Mirataz™ group and 94 cats were in the vehicle control group. The primary effectiveness endpoint was the mean percent change in body weight from Day 1 to the Week 2 Visit. At Week 2, the mean percent increase in body weight from Day 1 was 3.94% in the mirtazapine group and 0.41% in the vehicle control group. The difference between the two groups was significant (p<0.0001) based on a two-sample t-test assuming equal variances. A 95% confidence interval on the mean percent change in body weight for the Mirataz™ group is (2.77, 5.11), demonstrating that the mean percent change is statistically different from and greater than 0.

**STORAGE:** Store below 25°C (77°F). Multi-use tube. Discard within 30 days of first use.

**HOW SUPPLIED:** Mirataz™ is supplied in a 5 gram aluminum tube.

**MANUFACTURED FOR:**

Kindred Biosciences, Inc.  
1555 Bayshore Highway, suite 200  
Burlingame, CA 94010

**NADA 141-481, Approved by FDA**

Made in USA.  
NDC 86078-686-01  
REG-MTZBS-008 Rev. 26Apr2018

Mirataz™ is a trademark of Kindred Biosciences, Inc. ©2018 Kindred Biosciences, Inc. All rights reserved.

## Today's Veterinary Business Offers Free Resource Library to Practice Leaders

The new Veterinary Business Resource Library is a one-stop online shop for practice leaders. The library, powered by *Today's Veterinary Business*, serves as an invaluable tool for the veterinary practice, providing up-to-date assets and information from over 30 industry leading companies.

Originally an application run by *Veterinary Advantage* (an official publication of the NAVC), the tool was for distributor sales representatives who used it to send relevant materials to their customers and stay current on the latest product information.

With launch of the NAVC's *Today's Veterinary Business*, staff realized the app could fulfill a much larger purpose beyond being a tool for distributor sales reps only. It was a tool that had the potential to help the entire veterinary practice industry.

Today, the tool has been revamped so that the library's goal is to serve as the veterinary industry's source for product information, detailers, videos, and white papers. By hosting the most relevant information in a centralized repository, the resource library app places the information at the fingertips of veterinarians and their staff, minimizing the need to place inquiries with sales representatives.

The library app is free to end users and grants access to numerous resources. Veterinary practice members can visit an individual page for each company and browse their contact information, product details, and even SoundBytes (easy-to-read communication tool for about the product and pharmaceutical).

Whether you are looking for information on the latest vaccines, flea and tick control, lab products, test kits, exam room furnishings, supplements, or anything in between, check it out for yourself by visiting [veterinaryresourcelibrary.com](http://veterinaryresourcelibrary.com) **TVP**